Direct cell reprogramming for tissue engineering and regenerative medicine
Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat...
Uložené v:
| Vydané v: | Journal of biological engineering Ročník 13; číslo 1; s. 14 - 15 |
|---|---|
| Hlavní autori: | , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
13.02.2019
BioMed Central Ltd Springer Nature B.V BMC |
| Predmet: | |
| ISSN: | 1754-1611, 1754-1611 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields.
In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. |
|---|---|
| AbstractList | Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions.Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. Abstract Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to transition through an induced pluripotent state. Thus, it is an attractive approach to develop novel tissue engineering applications to treat diseases and injuries where there is a shortage of proliferating cells for tissue repair. In certain tissue damage, terminally differentiated somatic cells lose their ability to proliferate, as a result, damaged tissues cannot heal by themselves. Examples of these scenarios include myocardial infarctions, neurodegenerative diseases, and cartilage injuries. Transdifferentiation is capable of reprogramming cells that are abundant in the body into desired cell phenotypes that are able to restore tissue function in damaged areas. Therefore, direct cell reprogramming is a promising direction in the cell and tissue engineering and regenerative medicine fields. In recent years, several methods for transdifferentiation have been developed, ranging from the overexpression of transcription factors via viral vectors, to small molecules, to clustered regularly interspaced short palindromic repeats (CRISPR) and its associated protein (Cas9) for both genetic and epigenetic reprogramming. Overexpressing transcription factors by use of a lentivirus is currently the most prevalent technique, however it lacks high reprogramming efficiencies and can pose problems when transitioning to human subjects and clinical trials. CRISPR/Cas9, fused with proteins that modulate transcription, has been shown to improve efficiencies greatly. Transdifferentiation has successfully generated many cell phenotypes, including endothelial cells, skeletal myocytes, neuronal cells, and more. These cells have been shown to emulate mature adult cells such that they are able to mimic major functions, and some are capable of promoting regeneration of damaged tissue in vivo. While transdifferentiated cells have not yet seen clinical use, they have had promise in mice models, showing success in treating liver disease and several brain-related diseases, while also being utilized as a cell source for tissue engineered vascular grafts to treat damaged blood vessels. Recently, localized transdifferentiated cells have been generated in situ, allowing for treatments without invasive surgeries and more complete transdifferentiation. In this review, we summarized the recent development in various cell reprogramming techniques, their applications in converting various somatic cells, their uses in tissue regeneration, and the challenges of transitioning to a clinical setting, accompanied with potential solutions. Keywords: Cell reprogramming, Transdifferentiation, Gene editing, Epigenetics, Stem cells, Tissue engineering |
| ArticleNumber | 14 |
| Audience | Academic |
| Author | Dai, Guohao Grath, Alexander |
| Author_xml | – sequence: 1 givenname: Alexander surname: Grath fullname: Grath, Alexander organization: Department of Bioengineering, Northeastern University – sequence: 2 givenname: Guohao orcidid: 0000-0001-7346-2685 surname: Dai fullname: Dai, Guohao email: g.dai@northeastern.edu organization: Department of Bioengineering, Northeastern University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30805026$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kklv1TAUhS1URAf4AWxQJDZlkeIpdrxBqsr0UCUkhrXlODfBT4n9sJMK_j0OKW1fBSiJHF1_50Q-OcfowAcPCD0l-IyQWrxMhGEmSkxUfjgv1QN0RGTFSyIIObjzfoiOU9piXClK1SN0yHCNK0zFEfrw2kWwU2FhGIoIuxj6aMbR-b7oQiwml9IMBfjeeYC4jI1vM9iDh2gmdwXFCK2zefsxetiZIcGT6_UEfX375svF-_Ly47vNxfllaSVmU0kraYCTumOqFTVRpm5qKQStBYOG04pZpmRtSWUxIyDkcoNhpmOGE6oIO0Gb1bcNZqt30Y0m_tTBOP17EGKvTZycHUAb2jLGm1YKDLw21HCrGiEAM0zatm2y16vVazc3-RwW_BTNsGe6v-PdN92HKy2YzCHKbHB6bRDD9xnSpEeXljCNhzAnTfN_IhwLXGf0-T10G-boc1QLxTDnrJK3VG_yAZzvQv6uXUz1eSU5p0Qxlamzv1D5amF0Nrekc3m-J3ixJ8jMBD-m3swp6c3nT_vss7uh3KTxpzUZICtgY0gpQneDEKyXZuq1mTo3Uy_N1IupvKexbsoFCkuubvivkq7KtFsKCPE2t3-LfgFZ2fPW |
| CitedBy_id | crossref_primary_10_3389_fbioe_2021_748942 crossref_primary_10_1038_s41467_021_21801_4 crossref_primary_10_3389_fcell_2020_00809 crossref_primary_10_2478_aite_2025_0001 crossref_primary_10_1089_cell_2022_0102 crossref_primary_10_1089_regen_2021_0003 crossref_primary_10_1002_wsbm_1515 crossref_primary_10_1109_TCBB_2021_3133608 crossref_primary_10_1016_j_tibtech_2024_07_002 crossref_primary_10_3389_fcell_2022_927555 crossref_primary_10_1038_s41419_025_07863_y crossref_primary_10_1007_s10517_021_05099_2 crossref_primary_10_1002_adfm_201909882 crossref_primary_10_3233_STJ_200003 crossref_primary_10_1038_s41586_025_08844_z crossref_primary_10_1016_j_xnsj_2023_100235 crossref_primary_10_3390_jpm12081340 crossref_primary_10_1186_s11658_024_00581_x crossref_primary_10_1007_s42114_025_01331_z crossref_primary_10_3389_fimmu_2021_768458 crossref_primary_10_3390_cells8101189 crossref_primary_10_3390_bioengineering12090940 crossref_primary_10_1371_journal_pone_0255075 crossref_primary_10_1186_s12864_022_08612_7 crossref_primary_10_3389_fcvm_2020_00055 crossref_primary_10_1007_s12264_021_00729_1 crossref_primary_10_3390_ijms21207662 crossref_primary_10_1007_s12975_025_01331_7 crossref_primary_10_1016_j_bioactmat_2024_04_011 crossref_primary_10_3389_fbioe_2025_1558735 crossref_primary_10_3389_fchem_2023_1259435 crossref_primary_10_3390_cells12040618 crossref_primary_10_1186_s13148_021_01131_4 crossref_primary_10_3390_ijms26073063 crossref_primary_10_1515_tnsci_2020_0004 crossref_primary_10_1007_s11064_021_03282_5 crossref_primary_10_1016_j_jbc_2024_107994 crossref_primary_10_3389_fnmol_2019_00297 crossref_primary_10_3390_ijms221910211 crossref_primary_10_1002_bdr2_2007 crossref_primary_10_3390_cells11142142 crossref_primary_10_1002_smtd_202200798 crossref_primary_10_1038_s41598_020_78987_8 crossref_primary_10_1016_j_bioactmat_2022_07_021 crossref_primary_10_3390_cells12060930 crossref_primary_10_3390_ijms22179357 crossref_primary_10_1089_cell_2023_0015 crossref_primary_10_1002_adfm_201909553 crossref_primary_10_1016_j_bioactmat_2020_12_021 crossref_primary_10_1038_s12276_023_01003_2 crossref_primary_10_34133_research_0743 crossref_primary_10_1038_s41467_023_37256_8 |
| Cites_doi | 10.1016/S0925-4773(02)00337-4 10.1016/S0002-9440(10)65315-1 10.1073/pnas.1702295114 10.1124/pr.58.4.9 10.1016/j.neures.2007.11.006 10.1016/j.pneurobio.2013.11.001 10.1016/j.stem.2014.01.003 10.1002/ijc.23607 10.1016/j.neuroscience.2013.02.011 10.1371/journal.pone.0077365 10.1126/science.1231143 10.1007/s12015-010-9123-8 10.1038/nature10263 10.2337/diabetes.50.5.928 10.1038/nrm.2016.24 10.1186/s13287-015-0253-4 10.1126/science.1088547 10.1038/s41598-016-0001-8 10.1177/2041731416628329 10.1016/j.stem.2016.07.001 10.1002/term.2415 10.1073/pnas.1205526109 10.1242/jcs.202192 10.1073/pnas.1201701109 10.1038/cdd.2014.193 10.1161/CIRCRESAHA.116.304510 10.1007/s00223-006-0083-6 10.1007/978-1-61779-523-7_16 10.1016/j.stem.2017.06.011 10.1038/nrm.2016.6 10.1007/s13770-014-0099-3 10.1073/pnas.1103509108 10.1038/nmeth.3312 10.1038/nature08797 10.1161/CIRCRESAHA.116.309833 10.1007/s00223-011-9461-9 10.1038/nprot.2015.126 10.1146/annurev.biochem.70.1.81 10.1073/pnas.1303829110 10.1038/ncb2660 10.1089/cell.2014.0021 10.1161/CIRCULATIONAHA.113.007394 10.1016/j.ebiom.2017.01.015 10.1038/nature07314 10.1016/j.stemcr.2014.09.013 10.1038/s41419-017-0042-3 10.1038/nature21722 10.1016/j.cell.2007.11.019 10.3389/fphar.2014.00123 10.1007/s12072-013-9432-5 10.1016/j.biomaterials.2015.02.110 10.1038/nature10116 10.1016/j.cell.2006.06.044 10.1073/pnas.1720273115 10.1146/annurev-bioeng-071516-044720 10.1038/s41598-016-0028-x 10.1016/j.stem.2011.07.002 10.1242/jcs.132563 10.1016/j.stem.2015.05.014 10.1242/bio.016477 10.1146/annurev-bioeng-071516-044649 10.59566/IJBS.2008.4014 10.1111/jdi.12475 10.1016/j.stemcr.2016.09.013 10.1038/srep37540 10.1161/CIRCULATIONAHA.116.025722 10.1124/pr.115.010652 10.1038/ncomms13963 10.6064/2012/694137 10.1073/pnas.1413234112 10.1038/cr.2011.185 10.1016/j.bbrc.2016.04.076 10.1021/sb500322u 10.1038/nature11044 10.1111/j.1755-5922.2012.00320.x 10.1016/j.cell.2014.09.039 10.1038/s41598-018-22596-z |
| ContentType | Journal Article |
| Copyright | The Author(s). 2019 COPYRIGHT 2019 BioMed Central Ltd. Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s). 2019 – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: Copyright © 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION NPM ISR 3V. 7QO 7X7 7XB 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ HCIFZ K9. L6V LK8 M0S M7P M7S P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS 7X8 5PM DOA |
| DOI | 10.1186/s13036-019-0144-9 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed Gale In Context: Science ProQuest Central (Corporate) Biotechnology Research Abstracts Health & Medical Collection (ProQuest) ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Database Suite (ProQuest) ProQuest Technology Collection Natural Science Collection ProQuest One ProQuest Central Engineering Research Database Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Collection (ProQuest) ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection ProQuest Biological Science Collection ProQuest Health & Medical Collection Biological Science Database (ProQuest) Engineering Database Biotechnology and BioEngineering Abstracts Proquest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition Engineering Collection MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection ProQuest Engineering Collection Health Research Premium Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) Engineering Collection Engineering Database ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Materials Science & Engineering Collection Engineering Research Database ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Engineering Medicine |
| EISSN | 1754-1611 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_a2d334bd760e48a2a4c9b66e0301dddb PMC6373087 A574421939 30805026 10_1186_s13036_019_0144_9 |
| Genre | Journal Article Review |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: American Heart Association grantid: 12SDG12050083 funderid: http://dx.doi.org/10.13039/100000968 – fundername: National Science Foundation grantid: 1350240 funderid: http://dx.doi.org/10.13039/501100008982 – fundername: National Institute of Health grantid: R01HL118245; R21HD090680; R21HL102773 – fundername: ; grantid: 1350240 – fundername: ; grantid: 12SDG12050083 – fundername: ; grantid: R01HL118245; R21HD090680; R21HL102773 |
| GroupedDBID | --- 0R~ 29J 2WC 53G 5GY 5VS 7X7 8FE 8FG 8FH 8FI 8FJ AAFWJ AAJSJ AASML ABDBF ABJCF ABUWG ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADMLS ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BGLVJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EBD EBLON EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IHR ISR ITC KQ8 L6V LK8 M48 M7P M7S ML0 M~E O5R O5S OK1 OVT PGMZT PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC PTHSS PUEGO RBZ RNS ROL RPM RSV SEG SOJ TR2 TUS UKHRP ~8M AAYXX AFFHD CITATION 2VQ 4.4 AHSBF ALIPV C1A H13 IPNFZ NPM RIG 3V. 7QO 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ K9. P64 PJZUB PKEHL PPXIY PQEST PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c703t-257ae418f39d6819a8b87662863eb4253c3978c15c031e67e67eea3af3a412913 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 72 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000458653200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1754-1611 |
| IngestDate | Fri Oct 03 12:51:08 EDT 2025 Tue Nov 04 02:03:32 EST 2025 Sun Nov 09 13:56:47 EST 2025 Sat Oct 18 23:47:45 EDT 2025 Tue Nov 11 10:28:11 EST 2025 Tue Nov 04 17:56:23 EST 2025 Thu Nov 13 15:52:17 EST 2025 Thu Apr 03 07:07:39 EDT 2025 Sat Nov 29 03:24:56 EST 2025 Tue Nov 18 21:13:10 EST 2025 Sat Sep 06 07:23:02 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Epigenetics Cell reprogramming Tissue engineering Transdifferentiation Gene editing Stem cells |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c703t-257ae418f39d6819a8b87662863eb4253c3978c15c031e67e67eea3af3a412913 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0001-7346-2685 |
| OpenAccessLink | https://doaj.org/article/a2d334bd760e48a2a4c9b66e0301dddb |
| PMID | 30805026 |
| PQID | 2183044357 |
| PQPubID | 55249 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a2d334bd760e48a2a4c9b66e0301dddb pubmedcentral_primary_oai_pubmedcentral_nih_gov_6373087 proquest_miscellaneous_2186140608 proquest_journals_2183044357 gale_infotracmisc_A574421939 gale_infotracacademiconefile_A574421939 gale_incontextgauss_ISR_A574421939 pubmed_primary_30805026 crossref_primary_10_1186_s13036_019_0144_9 crossref_citationtrail_10_1186_s13036_019_0144_9 springer_journals_10_1186_s13036_019_0144_9 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-02-13 |
| PublicationDateYYYYMMDD | 2019-02-13 |
| PublicationDate_xml | – month: 02 year: 2019 text: 2019-02-13 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Journal of biological engineering |
| PublicationTitleAbbrev | J Biol Eng |
| PublicationTitleAlternate | J Biol Eng |
| PublicationYear | 2019 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | T Kogiso (144_CR23) 2013; 7 S Chakraborty (144_CR8) 2014; 3 S Sekiya (144_CR47) 2011; 475 ML Krakowski (144_CR50) 1999; 154 M Ruggieri (144_CR71) 2014; 114 Y Zhang (144_CR30) 2015; 5 K Zakikhan (144_CR49) 2016; 474 F Meng (144_CR6) 2012; 22 P Huang (144_CR24) 2014; 14 M Zurita (144_CR41) 2008; 60 M Lemper (144_CR65) 2015; 22 S Hacein-Bey-Abina (144_CR79) 2003; 302 SY Roth (144_CR29) 2001; 70 144_CR67 A Rubio (144_CR10) 2016; 6 T Vierbuchen (144_CR17) 2010; 463 CN Shen (144_CR33) 2003; 120 S Yin (144_CR61) 2010; 16 I Dufait (144_CR16) 2012; 2012 R Betz (144_CR52) 2002; 25 AM Kabadi (144_CR57) 2015; 4 H Ban (144_CR7) 2011; 108 K Takahashi (144_CR2) 2007; 131 H Outani (144_CR62) 2013; 8 L Cong (144_CR80) 2013; 339 P Huang (144_CR48) 2011; 475 L Vannucci (144_CR78) 2013; 36 HS Kim (144_CR63) 2016; 7 T Jayawardena (144_CR85) 2016; 116 R Ambasudhan (144_CR22) 2011; 9 144_CR53 W Schachterle (144_CR26) 2017; 8 K Kaur (144_CR13) 2014; 16 Y Tang (144_CR73) 2017; 8 Z Liu (144_CR59) 2008; 4 TH Qazi (144_CR60) 2015; 53 A Chavez (144_CR11) 2015; 12 H Yao (144_CR74) 2015; 10 J Zhang (144_CR82) 2017; 114 WT Wong (144_CR37) 2016; 7 G DeMaagd (144_CR72) 2015; 40 Z Chen (144_CR9) 2017; 19 AJ Merrell (144_CR15) 2016; 17 144_CR87 X Ni (144_CR70) 2016; 6 144_CR83 144_CR84 N Sayed (144_CR12) 2015; 131 JB Black (144_CR20) 2017; 19 144_CR86 N Lu (144_CR36) 2006; 58 L Zhang (144_CR56) 2017; 135 A Seki (144_CR81) 2018; 215 JB Black (144_CR43) 2016; 19 P Pham Van (144_CR55) 2016; 7 L Qian (144_CR75) 2012; 485 C Rouaux (144_CR77) 2013; 15 C Wang (144_CR28) 2017; 16 144_CR38 S Gascón (144_CR39) 2017; 21 A Margariti (144_CR25) 2012; 109 K Tanabe (144_CR27) 2018; 115 Y Komuta (144_CR18) 2016; 5 M Mall (144_CR44) 2017; 544 X Hong (144_CR68) 2017; 7 A Banga (144_CR76) 2012; 109 FD Gratte (144_CR51) 2018; 8 M Dominguez (144_CR19) 2012 ZD Smith (144_CR1) 2016; 17 N Naeem (144_CR14) 2013; 31 C Stresemann (144_CR32) 2008; 123 144_CR34 SM Boularaoui (144_CR58) 2018; 12 DK Smith (144_CR46) 2016; 7 S Lee (144_CR54) 2017; 120 K Hong (144_CR3) 2015; 12 M Patel (144_CR5) 2010; 6 144_CR69 JS Heo (144_CR42) 2013; 238 J Justesen (144_CR35) 2004 R Morita (144_CR4) 2015; 112 G Masserdotti (144_CR45) 2015; 17 O Torper (144_CR40) 2013; 110 Q Zhou (144_CR64) 2008; 455 JC Lee (144_CR66) 2001; 50 RT Kendall (144_CR21) 2014; 5 ME Tanenbaum (144_CR31) 2014; 159 |
| References_xml | – volume: 25 start-page: 561 year: 2002 ident: 144_CR52 publication-title: Ortho Blue J – volume: 120 start-page: 107 year: 2003 ident: 144_CR33 publication-title: Mech Dev doi: 10.1016/S0925-4773(02)00337-4 – volume: 154 start-page: 683 year: 1999 ident: 144_CR50 publication-title: Am J Pathol doi: 10.1016/S0002-9440(10)65315-1 – volume: 114 start-page: 6072 year: 2017 ident: 144_CR82 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1702295114 – volume: 58 start-page: 782 year: 2006 ident: 144_CR36 publication-title: Pharmacol Rev doi: 10.1124/pr.58.4.9 – volume: 60 start-page: 275 year: 2008 ident: 144_CR41 publication-title: Neurosci Res doi: 10.1016/j.neures.2007.11.006 – volume: 114 start-page: 15 year: 2014 ident: 144_CR71 publication-title: Prog Neurobiol doi: 10.1016/j.pneurobio.2013.11.001 – volume: 14 start-page: 370 year: 2014 ident: 144_CR24 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2014.01.003 – volume: 215 start-page: 985 year: 2018 ident: 144_CR81 publication-title: Cell – volume: 123 start-page: 8 year: 2008 ident: 144_CR32 publication-title: Int J Cancer doi: 10.1002/ijc.23607 – volume: 238 start-page: 305 year: 2013 ident: 144_CR42 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2013.02.011 – volume: 8 start-page: 4 year: 2013 ident: 144_CR62 publication-title: PLoS One doi: 10.1371/journal.pone.0077365 – volume: 339 start-page: 819 year: 2013 ident: 144_CR80 publication-title: Science doi: 10.1126/science.1231143 – volume: 6 start-page: 367 year: 2010 ident: 144_CR5 publication-title: Stem Cell Rev Reports doi: 10.1007/s12015-010-9123-8 – volume: 475 start-page: 390 year: 2011 ident: 144_CR47 publication-title: Nature doi: 10.1038/nature10263 – volume: 50 start-page: 928 year: 2001 ident: 144_CR66 publication-title: Diabetes doi: 10.2337/diabetes.50.5.928 – volume: 17 start-page: 413 year: 2016 ident: 144_CR15 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm.2016.24 – volume: 7 start-page: 1 year: 2016 ident: 144_CR55 publication-title: Stem Cell Res Ther doi: 10.1186/s13287-015-0253-4 – volume: 302 start-page: 415 year: 2003 ident: 144_CR79 publication-title: Science doi: 10.1126/science.1088547 – volume-title: Subcutaneous Adipocytes Can Differentiate into Bone-Forming Cells in Vitro and in Vivo *. 10 year: 2004 ident: 144_CR35 – volume: 6 start-page: 1 year: 2016 ident: 144_CR70 publication-title: Sci Rep doi: 10.1038/s41598-016-0001-8 – volume: 7 start-page: 1 year: 2016 ident: 144_CR37 publication-title: J Tissue Eng doi: 10.1177/2041731416628329 – volume: 19 start-page: 406 year: 2016 ident: 144_CR43 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2016.07.001 – volume: 12 start-page: 918 year: 2018 ident: 144_CR58 publication-title: J Tissue Eng Regen Med doi: 10.1002/term.2415 – volume: 109 start-page: 13793 year: 2012 ident: 144_CR25 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1205526109 – ident: 144_CR84 doi: 10.1242/jcs.202192 – volume: 109 start-page: 15336 year: 2012 ident: 144_CR76 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1201701109 – volume-title: High efficiency transfection of iCell cardiomyocytes and stem cell relevant cell sources year: 2012 ident: 144_CR19 – volume: 22 start-page: 1117 year: 2015 ident: 144_CR65 publication-title: Cell Death Differ doi: 10.1038/cdd.2014.193 – volume: 116 start-page: 418 year: 2016 ident: 144_CR85 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.116.304510 – volume: 40 start-page: 504 year: 2015 ident: 144_CR72 publication-title: P T – ident: 144_CR86 doi: 10.1007/s00223-006-0083-6 – ident: 144_CR69 doi: 10.1007/978-1-61779-523-7_16 – volume: 21 start-page: 18 year: 2017 ident: 144_CR39 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2017.06.011 – volume: 17 start-page: 139 year: 2016 ident: 144_CR1 publication-title: Nat Rev Mol Cell Biol doi: 10.1038/nrm.2016.6 – volume: 12 start-page: 80 year: 2015 ident: 144_CR3 publication-title: Tissue Eng Regen Med doi: 10.1007/s13770-014-0099-3 – volume: 108 start-page: 14234 year: 2011 ident: 144_CR7 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1103509108 – volume: 12 start-page: 326 year: 2015 ident: 144_CR11 publication-title: Nat Methods doi: 10.1038/nmeth.3312 – volume: 463 start-page: 1035 year: 2010 ident: 144_CR17 publication-title: Nature doi: 10.1038/nature08797 – volume: 120 start-page: 848 year: 2017 ident: 144_CR54 publication-title: Circ Res doi: 10.1161/CIRCRESAHA.116.309833 – ident: 144_CR87 doi: 10.1007/s00223-011-9461-9 – ident: 144_CR53 doi: 10.1038/nprot.2015.126 – volume: 10 start-page: 1 year: 2015 ident: 144_CR74 publication-title: PLoS One – volume: 70 start-page: 81 year: 2001 ident: 144_CR29 publication-title: Annu Rev Biochem doi: 10.1146/annurev.biochem.70.1.81 – volume: 110 start-page: 7038 year: 2013 ident: 144_CR40 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1303829110 – volume: 15 start-page: 214 year: 2013 ident: 144_CR77 publication-title: Nat Cell Biol doi: 10.1038/ncb2660 – ident: 144_CR38 – volume: 16 start-page: 324 year: 2014 ident: 144_CR13 publication-title: Cell Reprogram doi: 10.1089/cell.2014.0021 – volume: 5 start-page: 1 year: 2015 ident: 144_CR30 publication-title: Sci Rep – volume: 131 start-page: 300 year: 2015 ident: 144_CR12 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.007394 – volume: 16 start-page: 212 year: 2017 ident: 144_CR28 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2017.01.015 – volume: 455 start-page: 627 year: 2008 ident: 144_CR64 publication-title: Nature doi: 10.1038/nature07314 – volume: 36 start-page: 1 year: 2013 ident: 144_CR78 publication-title: Gene – volume: 3 start-page: 940 year: 2014 ident: 144_CR8 publication-title: Stem Cell Reports doi: 10.1016/j.stemcr.2014.09.013 – volume: 16 start-page: 1633 year: 2010 ident: 144_CR61 publication-title: Tissue Eng Regen Med – volume: 8 start-page: 1 year: 2017 ident: 144_CR73 publication-title: Cell Death Dis doi: 10.1038/s41419-017-0042-3 – volume: 544 start-page: 245 year: 2017 ident: 144_CR44 publication-title: Nature doi: 10.1038/nature21722 – volume: 131 start-page: 861 year: 2007 ident: 144_CR2 publication-title: Cell doi: 10.1016/j.cell.2007.11.019 – volume: 5 start-page: 1 year: 2014 ident: 144_CR21 publication-title: Front Pharmacol doi: 10.3389/fphar.2014.00123 – volume: 7 start-page: 937 year: 2013 ident: 144_CR23 publication-title: Hepatol Int doi: 10.1007/s12072-013-9432-5 – volume: 53 start-page: 502 year: 2015 ident: 144_CR60 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2015.02.110 – volume: 475 start-page: 386 year: 2011 ident: 144_CR48 publication-title: Nature doi: 10.1038/nature10116 – ident: 144_CR83 doi: 10.1016/j.cell.2006.06.044 – volume: 115 start-page: 6470 year: 2018 ident: 144_CR27 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1720273115 – volume: 19 start-page: 195 year: 2017 ident: 144_CR9 publication-title: Annu Rev Biomed Eng doi: 10.1146/annurev-bioeng-071516-044720 – volume: 7 start-page: 1 year: 2017 ident: 144_CR68 publication-title: Sci Rep doi: 10.1038/s41598-016-0028-x – volume: 9 start-page: 113 year: 2011 ident: 144_CR22 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2011.07.002 – ident: 144_CR34 doi: 10.1242/jcs.132563 – volume: 17 start-page: 74 year: 2015 ident: 144_CR45 publication-title: Cell Stem Cell doi: 10.1016/j.stem.2015.05.014 – volume: 5 start-page: 709 year: 2016 ident: 144_CR18 publication-title: Biol Open doi: 10.1242/bio.016477 – volume: 19 start-page: 249 year: 2017 ident: 144_CR20 publication-title: Annu Rev Biomed Eng doi: 10.1146/annurev-bioeng-071516-044649 – volume: 4 start-page: 14 year: 2008 ident: 144_CR59 publication-title: Int J Biomed Sci doi: 10.59566/IJBS.2008.4014 – volume: 7 start-page: 286 year: 2016 ident: 144_CR63 publication-title: J Diabetes Investig doi: 10.1111/jdi.12475 – volume: 7 start-page: 955 year: 2016 ident: 144_CR46 publication-title: Stem Cell Reports doi: 10.1016/j.stemcr.2016.09.013 – volume: 6 start-page: 1 year: 2016 ident: 144_CR10 publication-title: Sci Rep doi: 10.1038/srep37540 – volume: 135 start-page: 2505 year: 2017 ident: 144_CR56 publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.025722 – ident: 144_CR67 doi: 10.1124/pr.115.010652 – volume: 8 start-page: 1 year: 2017 ident: 144_CR26 publication-title: Nat Commun doi: 10.1038/ncomms13963 – volume: 2012 start-page: 1 year: 2012 ident: 144_CR16 publication-title: Scientifica (Cairo) doi: 10.6064/2012/694137 – volume: 112 start-page: 160 year: 2015 ident: 144_CR4 publication-title: Proc Natl Acad Sci doi: 10.1073/pnas.1413234112 – volume: 22 start-page: 436 year: 2012 ident: 144_CR6 publication-title: Cell Res doi: 10.1038/cr.2011.185 – volume: 474 start-page: 97 year: 2016 ident: 144_CR49 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2016.04.076 – volume: 4 start-page: 689 year: 2015 ident: 144_CR57 publication-title: ACS Synth Biol doi: 10.1021/sb500322u – volume: 485 start-page: 593 year: 2012 ident: 144_CR75 publication-title: Nature doi: 10.1038/nature11044 – volume: 31 start-page: 201 year: 2013 ident: 144_CR14 publication-title: Cardiovasc Ther doi: 10.1111/j.1755-5922.2012.00320.x – volume: 159 start-page: 635 year: 2014 ident: 144_CR31 publication-title: Cell doi: 10.1016/j.cell.2014.09.039 – volume: 8 start-page: 1 year: 2018 ident: 144_CR51 publication-title: Sci Rep doi: 10.1038/s41598-018-22596-z |
| SSID | ssj0059229 |
| Score | 2.4343526 |
| SecondaryResourceType | review_article |
| Snippet | Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the need to... Abstract Direct cell reprogramming, also called transdifferentiation, allows for the reprogramming of one somatic cell type directly into another, without the... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 14 |
| SubjectTerms | Animal models Apoptosis Applied Microbiology Biological Techniques Biomedical Engineering and Bioengineering Biotechnology Blood vessels Brain Brain injury Cartilage Cell division Cell reprogramming Clinical trials CRISPR Damage localization Disease DNA binding proteins Emerging leaders in biological engineering Endothelial cells Endothelium Engineering Environmental Engineering/Biotechnology Epigenetic inheritance Epigenetics Gene editing Genes Genetic engineering Grafts Heart attack Injuries Liver Liver diseases Medical research Medicine Methods Myocytes Nervous system diseases Neurodegenerative diseases Neurological diseases Neurons Nuclear reprogramming Nucleic Acid Chemistry Organ transplantation Phenotypes Physiological aspects Pluripotency Proteins Recovery of function Regeneration (physiology) Regenerative medicine Review Shortages Smooth muscle Somatic cells Stem cells Surgery Tissue engineering Transcription (Genetics) Transcription factors Transdifferentiation Vectors (Biology) |
| SummonAdditionalLinks | – databaseName: Biological Science Database (ProQuest) dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bi9UwEB50FdEHL-utukoVQXAp2zZpkzzJKi4quixeYN9CmqRHQdv1XPz9zqTpOdsV90U4T82EnmRmvpkk0y8Az6znvmzKKuOu5hkvDOKgKYpMVbbhwktZtIHE9YM4PJTHx-oobrgtYlnliIkBqF1vaY98j0J5zjG4i5cnvzK6NYpOV-MVGhfhErEklKF072hE4kqVpYonmYWs9xYBr3HxTBVCnGdqEosCZf_fwHwqMp2tmjxzdBoi0sGN_x3LTbgec9F0fzCeW3DBd9tw7RRD4TZc-RjP3m_D-wEdU9rqT4kLMxR2_USxFBPfdBk0mPpN79R0DgVngdiaUDUdD_LvwNeDN19ev83iTQyZRURYZujXxvNCtky5GnMIIxtEUfqqlfkGvZ5ZTGukLSqLGOFrQT9vmGmZ4ZhQFOwubHV95-9DaitrMIuxwoTkLW9y5UXpbNWqlhtlE8hHnWgbacrptowfOixXZK0HNWpUoyY1apXAi3WXk4Gj4zzhV6TotSDRa4cH_Xymo7dqUzrGeONEnXsuTWm4VU1de1o_OueaBJ6SmWgi0OioQmdmVouFfvf5k96vBOcYBhi-6XkUanscgTXxgwecB-LcmkjuTCTRw-20eTQjHRFmoTc2lMCTdTP1pKq5zverIIPZV17nMoF7g_Gux81wqVDhAjwBMTHrycRMW7rv3wL_eM0E8UgmsDs6wOZv_XPeH5w_iIdwtQyOWWYF24Gt5XzlH8Fl-xutd_44uPUfeqdSTw priority: 102 providerName: ProQuest – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5B4UAPlGcJFBQQEhIoahI7fhzbqhUgVKEWUG-WYzsLEmTRZpffz4yTbJvykEDa03qsXU9mPn-Ox58BnrvAQ1mXVca94BkvLOKgLYpMV67mMihVNFHE9Z08PlZnZ_r9cI67G6vdxy3JiNQxrZXY7SLa4tKX6ns4z_RVuIaznaL7Gk5OP43wW-my1MP25W-7TSagqNP_KxpfmI4ul0pe2i-N09DR1n8N4BbcHFhnuteHyW24Eto7sHlBi_AuvO3BL6U3-SlJXca6rW_YliKvTZfxAaXhvEtqW4-Gs6hbTaCZjvv09-Dj0eGHg9fZcNFC5jDhlxmmrQ28UA3TXiBFsKpGkKRDqyzUmNTMIWtRrqgcQkAQkj7BMtswy5EvFOw-bLTzNjyA1FXOIklx0kZulte5DrL0rmp0w612CeSj940bVMjpMoyvJq5GlDC9mwy6yZCbjE7g5brL916C42_G-_RI14aknh2_mC9mZkhGY0vPGK-9FHngypaWO10LEWh56L2vE3hGAWFIH6OlApyZXXWdeXN6YvYqyTmiPMNfejEYNXMcgbPDeQb0A0lqTSx3JpaYwG7aPMadGQCkM8Rcc45cVibwdN1MPakorg3zVbRBcpWLXCWw3YfpetwMVwIVrq8TkJMAnjhm2tJ--RzlxQWTJBOZwKsxjM__1h_9_vCfrB_BjTLmQZkVbAc2lotVeAzX3Q8M5sWTmM8_AezjRJw priority: 102 providerName: Springer Nature |
| Title | Direct cell reprogramming for tissue engineering and regenerative medicine |
| URI | https://link.springer.com/article/10.1186/s13036-019-0144-9 https://www.ncbi.nlm.nih.gov/pubmed/30805026 https://www.proquest.com/docview/2183044357 https://www.proquest.com/docview/2186140608 https://pubmed.ncbi.nlm.nih.gov/PMC6373087 https://doaj.org/article/a2d334bd760e48a2a4c9b66e0301dddb |
| Volume | 13 |
| WOSCitedRecordID | wos000458653200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: RBZ dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: DOA dateStart: 20070101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: M~E dateStart: 20070101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: M7P dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Engineering Database customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: M7S dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content Database customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1754-1611 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0059229 issn: 1754-1611 databaseCode: RSV dateStart: 20071201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_B4AEeEJ8jMKqAkJBA0ZLY8cfjhjYxBFXVAipPluM4A2lL0dry93PnJF0zBLwgVZHaOyvJ5T5-ri8_A7x0nvu8zIuEV4InPLOYB22WJbpwJZdeqawOJK4f5His5nM92drqi3rCWnrg1nD7Nq8Y42UlReq5srnlTpdCeILyVVWVlH1TqfvJVJuDC53nulvDzJTYX4ZMjdNm6g3iPNGDKhTI-n9PyVs16Wq_5JVF01CLju_CnQ5Exgftxd-Da765D7e3qAUfwPs2l8X0x3xMzJWhDescZTHC1HgV7B37yyGxbSpUPA001JQD437Z_SF8Pj769PZd0u2bkDiM31WCUWg9z1TNdCWw4ltVYs6jd1CZLzFGmUMQolxWOIxoLyR9vGW2ZpZj-c_YI9hpFo1_DLErnEXM4aQNUCstU-1lXrmi1jW32kWQ9nY0riMVp70tzkyYXChhWtMbNL0h0xsdwevNkB8to8bflA_p4WwUiQw7_IAuYjoXMf9ykQhe0KM1RHfRUD_NqV0vl-ZkNjUHheQckzbDM73qlOoF3oGz3esJaAdiyBpo7g00MR7dUNx7kOnywdIQEE05QlMZwfONmEZSj1vjF-ugg1gpFamKYLd1uM19MwT2BU6XI5ADVxwYZihpvn8LbOGCSWJ9jOBN77SXl_VHuz_5H3Z_CrfyEHJ5krE92FldrP0zuOl-oo9fjOC6nMtwVCO4cXg0nkxHIYhH1H87CccZSiYnHydf8dt09uUXLbJJ6Q |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD4aHeLywGXcAgMCAiGBoiW2c3tAaFymlbVVBUMaT8ZxnIIE6WhaEH-K38g5TtIuQ-xtD0h9qo_b2P18vnPq488Aj7QRhmUs9EQeCU8ECv2gCgIvDXUmYpMkQWFFXAfxaJQcHKTjNfjdnoWhssrWJ1pHnU81_Ue-RVTuCyT3-MXhd49ujaLd1fYKjRoWe-bXT0zZquf91_j7PmZs583-q12vuVXA04juuYcYVUYEScHTPEI-VEmGHoFOaHKTIYK5RopOdBBqxLuJYnoZxVXBlUByDDh-7hlYFwT2HqyP-8Pxx9b3hyljabN3GiTRVmUZAtN1qkkSwks77GcvCfibCo5w4fE6zWObtZYDdy7_b7N3BS410ba7XS-Pq7Bmyg24eESDcQPODZvqgmvwtvb_Lm1muKT2aUvXvqGZi6G9O7cYdc2qt6vKHA0nVrqbeMNtSxWuw4dTGdcN6JXT0twCV4daYZymY2XDUz_zUxOzXIdFWgiVagf8FgNSN0LsdB_IV2kTsiSSNWwkwkYSbGTqwNNll8NaheQk45cErKUhCYjbN6aziWz8kVQs51xkeRz5RiSKKaHTLIoMZch5nmcOPCRYSpIIKakGaaIWVSX779_J7TBG8GPgj9_0pDEqpjgCrZojHTgPpCrWsdzsWKIP093mFray8aGVXGHWgQfLZupJdYGlmS6sDcaXfuQnDtysF8ty3ByTodBnkQNxZxl1JqbbUn75bBXWIx6TUqYDz9oFt3qsf8777ZMHcR_O7-4PB3LQH-3dgQvMOgXmBXwTevPZwtyFs_oHInl2r3EqLnw67ZX4BzHerdM |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwEB5BQQgeuI9AgYCQkIqiJrFjx4_lWFGoVhUF1DfLsZ1tJchWm11-PzNOsm3KISGkfYrHyno883kmHn8GeGE993mVFwl3gic8M4iDJssSVdiKS1-WWR1IXPfkdFoeHqr9_p7Tdqh2H7YkuzMNxNLULLdPXN25eCm224C8mAZTrQ_niboIlzjV0VO6fvB1gOJC5bnqtzJ_2220GAXO_l-R-czSdL5s8tzeaViSJjf-ezA34XofjcY7nfncggu-uQ3XznAU3oEPHSjG9IU_JgrMUM_1HdtijHfjZZi42J92iU3jUHAW-KwJTONh__4ufJm8-_zmfdJfwJBYBIJlgu5sPM_KmiknMHQwZYXgSYdZma_Q2ZnFaKa0WWERGryQ9POGmZoZjnFExu7BRjNv_AOIbWENBi9WmhCzpVWqvMydLWpVc6NsBOkwE9r27OR0ScY3HbKUUuhOTRrVpElNWkWwte5y0lFz_E34NU3vWpBYtcOD-WKmeyfVJneM8cpJkXpemtxwqyohPKWNzrkqgudkHJp4MxoqzJmZVdvq3YNPeqeQnCP6M3zTy16onuMIrOnPOaAeiGprJLk5kkTHtuPmwQZ1Dyytpog25RjjygierZupJxXLNX6-CjIYdKUiLSO435nsetwMM4QC8-4I5MiYR4oZtzTHR4F2XDBJ9JERvBpM-vRv_VHvD_9J-ilc2X870Xu704-P4GoeXCJPMrYJG8vFyj-Gy_YH2vXiSXDzn0AIUGQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Direct+cell+reprogramming+for+tissue+engineering+and+regenerative+medicine&rft.jtitle=Journal+of+biological+engineering&rft.au=Grath%2C+Alexander&rft.au=Dai%2C+Guohao&rft.date=2019-02-13&rft.issn=1754-1611&rft.eissn=1754-1611&rft.volume=13&rft.spage=14&rft_id=info:doi/10.1186%2Fs13036-019-0144-9&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1754-1611&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1754-1611&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1754-1611&client=summon |